Kaposi sarcoma-associated herpesvirus: Difference between revisions
From IDWiki
(Created page with "== Background == * Seroprevalence variés by geography and group ** US general population 1-5% ** US men who have sex with men 15-20% ** US MSM with HIV 30-35% ** Some Mediterranean countries 10-20% ** Sub-Saharan African countries 30-80% == Clinical Manifestations == * Mostly asymptomatic * Kaposi sarcoma == Management == * See Kaposi sarcoma Category:Human herpesviruses") |
(added a few other clinical manifestations) |
||
Line 10: | Line 10: | ||
* Mostly asymptomatic |
* Mostly asymptomatic |
||
* [[Kaposi sarcoma]] |
* [[Kaposi sarcoma]] |
||
* Primary effusion lymphoma (PEL) |
|||
** Causes effusions isolated within the pleural, pericardial, or abdominal cavities |
|||
** Occasionally causes mass lesions and extracavitary disease within skin, hematopoietic organs, and the GI |
|||
* Multicentric Castleman disease (MCD) |
|||
** Causes systemic symptoms including fever and night sweats, generalized adenopathy, fever, and hepatosplenomegaly |
|||
== Management == |
== Management == |
Revision as of 18:14, 1 October 2022
Background
- Seroprevalence variés by geography and group
- US general population 1-5%
- US men who have sex with men 15-20%
- US MSM with HIV 30-35%
- Some Mediterranean countries 10-20%
- Sub-Saharan African countries 30-80%
Clinical Manifestations
- Mostly asymptomatic
- Kaposi sarcoma
- Primary effusion lymphoma (PEL)
- Causes effusions isolated within the pleural, pericardial, or abdominal cavities
- Occasionally causes mass lesions and extracavitary disease within skin, hematopoietic organs, and the GI
- Multicentric Castleman disease (MCD)
- Causes systemic symptoms including fever and night sweats, generalized adenopathy, fever, and hepatosplenomegaly
Management
- See Kaposi sarcoma